Canoe Financial LP Grows Stock Position in Johnson & Johnson $JNJ

Canoe Financial LP boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 613.8% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 505,569 shares of the company’s stock after buying an additional 434,743 shares during the period. Canoe Financial LP’s holdings in Johnson & Johnson were worth $104,628,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently modified their holdings of JNJ. Lineweaver Wealth Advisors LLC lifted its holdings in shares of Johnson & Johnson by 2.4% during the 4th quarter. Lineweaver Wealth Advisors LLC now owns 24,141 shares of the company’s stock worth $4,996,000 after acquiring an additional 569 shares during the period. Chesley Taft & Associates LLC grew its holdings in Johnson & Johnson by 7.5% in the fourth quarter. Chesley Taft & Associates LLC now owns 212,903 shares of the company’s stock valued at $44,060,000 after purchasing an additional 14,776 shares during the period. Cypress Wealth Services LLC increased its position in Johnson & Johnson by 71.2% during the fourth quarter. Cypress Wealth Services LLC now owns 12,272 shares of the company’s stock worth $2,540,000 after purchasing an additional 5,103 shares during the last quarter. Waldron Private Wealth LLC increased its position in Johnson & Johnson by 0.6% during the fourth quarter. Waldron Private Wealth LLC now owns 25,844 shares of the company’s stock worth $5,348,000 after purchasing an additional 144 shares during the last quarter. Finally, LVW Advisors LLC raised its stake in Johnson & Johnson by 1.7% during the fourth quarter. LVW Advisors LLC now owns 24,623 shares of the company’s stock worth $5,096,000 after purchasing an additional 402 shares during the period. Institutional investors and hedge funds own 69.55% of the company’s stock.

Insider Activity

In related news, EVP Vanessa Broadhurst sold 6,197 shares of the firm’s stock in a transaction dated Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the sale, the executive vice president directly owned 23,003 shares in the company, valued at approximately $5,598,700.17. This trade represents a 21.22% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP Timothy Schmid sold 1,322 shares of the company’s stock in a transaction that occurred on Friday, February 20th. The stock was sold at an average price of $245.66, for a total value of $324,762.52. Following the completion of the transaction, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,251,310.02. This represents a 4.94% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 30,142 shares of company stock worth $7,360,528. Company insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently issued reports on JNJ shares. Loop Capital set a $220.00 price objective on shares of Johnson & Johnson in a research note on Tuesday, January 27th. Bank of America reiterated a “neutral” rating on shares of Johnson & Johnson in a report on Monday, March 2nd. Leerink Partners boosted their price target on Johnson & Johnson from $201.00 to $232.00 and gave the company a “market perform” rating in a research report on Thursday, January 22nd. Daiwa Securities Group raised their price objective on Johnson & Johnson from $203.00 to $237.00 and gave the stock an “outperform” rating in a report on Thursday, January 29th. Finally, Weiss Ratings reaffirmed a “buy (b)” rating on shares of Johnson & Johnson in a research note on Wednesday, January 28th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and nine have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average target price of $236.91.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $242.22 on Tuesday. The firm’s fifty day simple moving average is $237.87 and its 200 day simple moving average is $211.39. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.48. Johnson & Johnson has a twelve month low of $141.50 and a twelve month high of $251.71. The firm has a market capitalization of $583.40 billion, a price-to-earnings ratio of 21.92, a PEG ratio of 2.37 and a beta of 0.34.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Saturday, January 31st. The company reported $2.46 earnings per share (EPS) for the quarter. Johnson & Johnson had a return on equity of 33.04% and a net margin of 28.46%.The firm had revenue of $24.28 billion during the quarter. As a group, equities research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th were paid a $1.30 dividend. The ex-dividend date was Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.1%. Johnson & Johnson’s dividend payout ratio (DPR) is 47.06%.

Key Stories Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Royalty Pharma agreed to provide $500 million of R&D co‑funding for JNJ‑4804, a novel co‑antibody targeting IL‑23 and TNF; the deal de‑risks development costs, validates the program and accelerates immunology exposure for J&J. Royalty Pharma and J&J partner to develop autoimmune treatment Johnson & Johnson’s JNJ-4804 Deal Adds Weight To Immunology Story
• Positive Sentiment: J&J presented first randomized Phase 2 data for JNJ‑1900 (NBTXR3) in stage‑3 inoperable lung cancer at a major conference — early positive clinical readouts support the oncology pipeline and partner collaborations. NANOBIOTIX Announces Presentation of First Data
• Positive Sentiment: Johnson & Johnson MedTech shared favorable findings for the Impella CP device in left‑ventricular support at ACC, which may support near‑term MedTech revenue momentum and competitive positioning. Johnson & Johnson MedTech shares findings for Impella CP
• Positive Sentiment: Royal Bank of Canada reaffirmed an “outperform” rating and a $255 price target, providing analyst backing that supports upside expectations versus current levels. RBC reaffirmation / Benzinga
• Positive Sentiment: Multiple outlets highlighted J&J as a top dividend/defensive stock and noted an upcoming dividend increase window — this bolsters demand from income and defensive investors given J&J’s low beta and long dividend history. This is Why Johnson & Johnson is a Great Dividend Stock Dividend increases coverage
• Neutral Sentiment: Industry research forecasts growth in the non‑muscle invasive bladder cancer market and lists J&J among leading competitors — a positive long‑term market backdrop but not an immediate catalyst. Non‑Muscle Invasive Bladder Cancer Market report

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.